Senolytics Treatment of Interstitial Lung Disease in Common Variable Immunodeficiency

Part of paid clinical trials in Rochester, Minnesota.

Sponsor
Avni Joshi
Study ID
NCT05593588
Phase
PHASE2
Status
Enrolling By Invitation

Conditions

  • Common Variable Immunodeficiency
  • Interstitial Lung Disease Due to Systemic Disease

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Fisetin — DRUG
    20 mg per kilogram (kg) of body weight supplied in 100 mg capsules and administered orally on days 0, 1, 28, and 29
  • Placebo — DRUG
    Looks exactly like the study drug, but it contains no active ingredient. Administered orally on days 0, 1, 28 and 29

Study Details

The purpose of this study is to determine if the supplement, Fisetin, can be used as a treatment option for common variable immunodeficiency (CVID) by comparing its efficacy to placebo.

Key Dates

Start date
Apr 12, 2023
Status verified
Jan 2026
Primary completion
May 31, 2026
Completion
Dec 31, 2026

Study Design

Enrollment
20 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Fisetin Group
    Subjects will receive the supplement, Fisetin, for 2 cycles of 2 consecutive days (first on days 0 \& 1 and then repeated on days 28 \& 29)
  • Placebo Comparator: Placebo Group
    Subjects will receive placebo for 2 cycles of 2 consecutive days (first on days 0 \& 1 and then repeated on days 28 \& 29)

Primary Outcome Measure

Change in immunophenotyping of peripheral T lymphocytes [ Time Frame: Baseline, 6 months ]

Locations (1)

FacilityCityStateZIPSite coordinators
Mayo Clinic in RochesterRochesterMinnesota55905-

Find similar trials in Rochester, MN

By research site
Mayo Clinic in Rochester· Rochester, MN

Related Studies